Vesugen

Vesugen is marketed as a blood-vessel peptide and an anti-aging ('geroprotector') peptide, though the 'vascular' label reflects how the Russian 'Khavinson' bioregulator family assigns each peptide to an organ more than actual blood-vessel research — its newest cell studies are about nerve cells; two older lab studies from the same Russian institute looked at blood-vessel cells. It's a synthetic three-amino-acid peptide (Lys-Glu-Asp). It is not an FDA-approved drug, and the evidence is preclinical plus one small Russian study, with no large controlled trials.

Vesugen is marketed for blood vessels, and two older lab studies from the same Russian institute looked at vessel-lining cells. A small Russian study in 32 aged patients reported anabolic and nervous-system benefits and slowed "biological age" markers, though it also noted concerning signals (a prooxidant effect and reduced circulating stem-cell markers). The newer laboratory work is all on nerve cells — markers of neuronal differentiation, more branching in neurons from elderly donors, and lower cell-aging markers. It fits a broad tissue-specific peptide theory but is small and preliminary, all from one research institute, with no large controlled trials.

Not a drug in the US and not FDA-approved for any indication. A synthetic "Khavinson" short-peptide bioregulator ("cytogen") from the St. Petersburg Institute of Bioregulation and Gerontology (Russia). The "vascular" tissue label comes from the Khavinson family's tissue-assignment framework, with little direct evidence behind it — the newest cell studies of KED are all in neurons and neuronal differentiation; two older cell-culture studies of vessel-lining (endothelial) cells exist, from the same Russian institute. Evidence is preclinical plus one small non-blinded Russian human study; no large controlled trials. WADA: not specifically named; best treated as S0 (non-approved), prohibited at all times — verify with your anti-doping organization. Not DEA-scheduled. Also not on FDA's 503A list of bulk substances permitted for pharmacy compounding.

Vesugen has only small, non-blinded human data and is not FDA-approved. One study noted potential downsides (a prooxidant effect and reduced circulating stem-cell markers) that are not fully understood. It is not a treatment for any vascular or aging condition. As a non-approved research peptide it is best treated as prohibited in regulated sport (WADA S0). VialWise is a research and educational reference, not medical advice.

⚠️ Vesugen is not FDA-approved and is not a treatment for any vascular or age-related condition. Its evidence is preclinical plus small, non-blinded human studies. Information here is informational, not medical advice.

⚠️ Part of the Khavinson "bioregulator" family — read the shared caveat. Vesugen is one of a set of short peptides from the St. Petersburg Institute of Bioregulation and Gerontology. The whole family shares a thin, mostly-preclinical, largely single-institute evidence base and no large controlled trials.[³]

⚠️ A human study noted potential downsides. The small aged-patient study reported a prooxidant effect and reduced circulating stem-cell (CD34+) markers alongside its claimed benefits[¹] — signals the authors themselves flagged for further study. Do not read Vesugen as clearly safe.

⚠️ The "vascular" label has little direct support in the published mechanism data. Vesugen is marketed and cataloged as a vascular-wall bioregulator, but the newest cell-mechanism studies of KED are all neuronal — neuronal differentiation of stem cells,[²] dendritic arborization in neurons derived from elderly donors,[⁴] and cell-senescence markers in induced neurons.[⁵] Two older cell-culture studies of vascular endothelial cells exist, from the same institute,[⁷][⁸] and neither tested a vascular effect in people. The vascular designation reflects the Khavinson family's tissue-assignment framework more than vascular data. (The one human study's "vascular" wording describes the patients' condition — organic brain syndrome of vascular or traumatic origin — not a vascular effect of the peptide.)

Vesugen is a synthetic tripeptide, Lys-Glu-Asp (KED), in the "Khavinson" short-peptide bioregulator family, assigned to the vascular (blood-vessel) wall by that family's tissue framework, and marketed as a geroprotector. According to PubMed: - A small Russian study of 32 aged patients (41–83) with chronic polymorbidity and organic brain syndrome in remission gave Vesugen and Pinealon and reported a significant anabolic effect and improved CNS/organ function with slowing of biological-age markers; the authors judged Vesugen's effect more visible than Pinealon's — but also found a prooxidant signal by chemiluminescence and a decrease in circulating CD34+ hematopoietic cell markers, which they described as significant inhibition of hemopoiesis and flagged as needing further study.[¹] - The newest cell work is neuronal. KED was among peptides studied for neuronal differentiation of human periodontal-ligament stem cells,[²] and in a newer in-vitro aging model KED (with EDR and AEDG) was reported to promote dendritic arborization in induced neurons derived from elderly donors' fibroblasts.[⁴] A 2025 study reported that AEDG and KED lowered the cell-cycle marker p21 by 15% and beta-galactosidase activity 1.51–2.4-fold in induced neurons, while not changing TUj-1 or LaminB1.[⁵] A Russian-language review lists Lys-Glu-Asp among multitarget short peptides discussed for Alzheimer's disease.[⁶] - Two older cell-culture studies from the same institute looked at vascular endothelial cells (the cells lining blood vessels). In cultures from young and old animals, including endothelial cultures, vesugen was reported to stimulate the proliferation marker Ki-67, which declines with aging;[⁷] and KED was reported to normalize endothelin-1 expression, restore cell-to-cell interactions via connexin expression, and raise sirtuin-1 expression in normal, atherosclerotic and restenotic endothelium in vitro.[⁸] Both are lab results; neither tested a vascular effect in people.

The tissue label rests on thin evidence. Two PubMed-indexed studies of KED in blood-vessel cells exist, the older cell-culture studies above,[⁷][⁸] both from the same institute that assigns the label; the "vascular bioregulator" designation comes from the Khavinson family's organ-assignment scheme, and the newer research has moved to nerve cells. That is worth stating plainly — but note it cuts both ways: the neuronal findings are cell-culture results and do not establish Vesugen as a neurological compound either.

Evidence quality. Limited — one small, non-blinded human study plus cell work, all traceable to the St. Petersburg Institute of Bioregulation and Gerontology and its collaborators. The additional sources are the same research tradition, not independent replication. No large controlled trials. See the shared Khavinson caveat below.

### About the Khavinson bioregulators (shared framing)

Developed from the 1970s by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, these cytomedin/cytogen peptides went from organ-extract complexes to synthetic short peptides proposed to have tissue-specific effects under a "peptide theory of ageing."[³] Honest caveats: evidence is overwhelmingly preclinical plus small, often non-blinded Russian studies; no large independent randomized trials; none FDA-approved; sold in Russia as injectables and supplements.

Regulatory status (US). Not FDA-approved; not a drug. Not DEA-scheduled. Also not on FDA's 503A list of bulk substances permitted for pharmacy compounding.

Regulatory status (sport — WADA). Not specifically named; best treated as S0 (non-approved), prohibited at all times. Verify with your anti-doping organization.

Common research interests. Vascular and general anti-aging ("geroprotector") support. The vascular interest comes mainly from the family's tissue-assignment label, backed by two older single-institute cell-culture studies,[⁷][⁸] and neither it nor the geroprotector framing is an established human use.

Commonly reported

• Prooxidant activity (increased oxidative signal)
• Reduced circulating CD34+ stem-cell markers (possible hematopoietic inhibition) — authors flagged for further study
• Injection-site reactions
• Reactions to research-supply material of variable purity
• Unknown long-term safety, especially given the flagged signals above.

Not a treatment for any vascular or aging condition — see a clinician

Pregnancy and lactation — no data; default to contraindicated

Pediatric use — no data; not for researchers under 18

Conditions sensitive to oxidative stress or reduced hematopoiesis — caution given the flagged signals[¹]

Known hypersensitivity — contraindicated

Regulatory note (US): Not FDA-approved; not DEA-scheduled.

Regulatory note (sport): Best treated as WADA S0. Verify with your anti-doping organization.

Bioregulator (Khavinson peptide)

A very short synthetic peptide from the St. Petersburg Institute of Bioregulation and Gerontology, each assigned to one tissue by the family's own framework. For Vesugen that assignment is blood vessels, but its newest cell research is on neurons.

Geroprotector

A compound claimed to slow aging. Vesugen is marketed this way, on limited evidence.

Prooxidant

Something that can increase oxidative stress — a potential downside noted in the Vesugen human study.

Non-blinded study

A study where participants/researchers knew the treatment, which weakens the reliability of the result.

1. Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE. (2015). [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]. Advances in Gerontology (Uspekhi Gerontologii), 28(1):62–67.(PMID 26390612)
2. Caputi S, Trubiani O, Sinjari B, Trofimova S, Diomede F, Linkova N, Diatlova A, Khavinson V. (2019). Effect of short peptides on neuronal differentiation of stem cells. International Journal of Immunopathology and Pharmacology, 33:2058738419828613.(PMID 30791821)
3. Khavinson VKh. (2002). Peptides and Ageing. Neuro Endocrinology Letters, 23 Suppl 3:11–144.(PMID 12374906)
4. Kraskovskaya N, Linkova N, Sakhenberg E, Krieger D, Polyakova V, Medvedev D, Krasichkov A, Khotin M, Ryzhak G. (2024). Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International Journal of Molecular Sciences, 25(21):11363.(PMID 39518916)
5. Sakhenberg E, Linkova N, Kraskovskaya N, Krieger D, Polyakova V, Medvedev D, Krasichkov A, Khotin M, Ryzhak G. (2025). The Influence of Short Peptides on Cell Senescence and Neuronal Differentiation. Current Issues in Molecular Biology, 47(9):739.(PMID 41020860)
6. Ilina AR, Popovich IG, Ryzhak GA, Khavinson VK. (2024). [Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer's disease]. Advances in Gerontology, 37(1-2):10–20. Russian-language; no DOI indexed.(PMID 38944767)
7. Khavinson VKh, Tarnovskaia SI, Lin'kova NS, Guton EO, Elashkina EV. (2014). [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. Advances in Gerontology (Uspekhi Gerontologii), 27(1):108–14.(PMID 25051766)
8. Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM, Kozina LS. (2016). [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Advances in Gerontology (Uspekhi Gerontologii), 29(4):646–650.(PMID 28539025)

• Pinealon — discussed together in this entry's stacks section
• Bronchogen — same mechanism class
• Cardiogen — same mechanism class
• Cartalax — same mechanism class
• Chonluten — same mechanism class
• Cortagen — same mechanism class